Evolving Treatment Options for Transplant-Ineligible Multiple Myeloma
Before closing out his discussion on transplant-ineligible multiple myeloma, Rafael Fonseca, MD, considers the future roles of CAR T-cell and bispecific antibody therapies.
Novel Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma
Expert perspectives on two bispecific antibodies, teclistamab and talquetamab, that have been investigated in multiply relapsed multiple myeloma.
Novel CAR T-Cell Therapies for Relapsed/Refractory Multiple Myeloma
Shared insight on two novel CAR T-cell therapies, cilta-cel and ide-cel, that have been tested in multiply relapsed multiple myeloma.
Treatment Armamentarium for Relapsed/Refractory Multiple Myeloma
Rafael Fonseca, MD, shares an overview of the treatment armamentarium for patients with relapsed/refractory multiple myeloma.
Optimizing the Management of Transplant-Ineligible NDMM: Depth and Durability of Response
Practical advice on strategies to improve care for patients with transplant-ineligible multiple myeloma regarding induction and maintenance therapy, and aiming for deep and durable responses.
Updated Data from the MAIA Trial in Transplant-Ineligible MM
Expert perspectives on updated data from the MAIA trial in newly diagnosed transplant-ineligible multiple myeloma and how this can be applied to clinical practice.
A Case of Transplant-Ineligible MM: Frontline Daratumumab-based Triplet Therapy
Rafael Fonseca, MD, provides details on a patient case of transplant-ineligible multiple myeloma and reviews the selection of frontline triplet versus doublet therapy.
Phase 3 MAIA Trial Review
Rafael Fonseca, MD, reviews efficacy and safety data from the phase 3 MAIA trial and discusses their implications for clinical practice.
Role of Monoclonal Antibodies in Up-front Therapy for Multiple Myeloma
Rafael Fonseca, MD, discusses the role of monoclonal antibodies in the first-line setting in patients with newly diagnosed multiple myeloma.
Considerations for Selecting First-Line Therapy in Newly Diagnosed Multiple Myeloma
Rafael Fonseca, MD, reviews first-line therapy options and considerations for treatment selection for patients with newly diagnosed multiple myeloma.
Initial Impressions: Goals and Challenges
Rafael Fonseca, MD, discusses the challenges of treating patients with newly diagnosed multiple myeloma.
Case Overview: Multiple Myeloma
Rafael Fonseca, MD, reviews the case overview of a 77-year-old woman with multiple myeloma.
A 77-Year-Old Woman With Multiple Myeloma
Rafael Fonseca, MD, discusses the case of a 77-year-old woman with multiple myeloma, treatment approach for patients with newly diagnosed multiple myeloma, and the trials providing insight into the treatment of this disease.
Roundtable Discussion: Fonseca Leads Debate on the Use of Minimal Residual Disease in Multiple Myeloma
During a virtual Targeted Oncology Case-Based Roundtable event, Rafael Fonseca, MD, lead a discussion on how MRD status can guide treatment of multiple myeloma
2 Clarke Drive Cranbury, NJ 08512